Hepatopulmonary syndrome and portopulmonary hypertension

Current Treatment Options in Cardiovascular Medicine

Volumn 4, Issue 3, 2002, Pages 267-273

  Krowka, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Epoprostenol; Portal Hypertension; Pulmonary Artery Pressure; Pulmonary Hypertension; Transjugular Intrahepatic Portosystemic Shunt

Indexed keywords

EID: 3242777192     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-002-0007-3     Document Type: Article

References (39)

1. Krowka MJ: Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997, 25:1282–1284. A practical primer that clarifies the differences in diagnostic criteria, screening, and outcomes between these pulmonary vascular syndromes.
2. Krowka MJ: Hepatopulmonary syndromes. Gut 2000, 46:1–4.
3. Martinez G, Barabera JA, Navasa M, et al.: Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 1999, 30:882–889.
4. Castro M, Krowka MJ, Schroeder DR, et al.: Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996, 71:543–551.
5. Saunders KB, Frenando SSD, Dalton HR, et al.: Spontaneous improvement in a patient with hepatopulmonary syndrome assessed by serial exercise tests. Thorax 1994, 49:725–727.
6. Song JY, Choi JY, Ko JT, et al.: Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics 1996, 97:917–920.
7. Krowka MJ, Cortese DA: Severe hypoxemia associated with liver disease: Mayo Clinic experience and experimental use of almitrine bismesylate. Mayo Clin Proc 1987, 62:164–173.
8. Shijo H, Sasaki H, Yuh K, et al.: Effects of indomethacin on hepatogenic pulmonary angiodysplasia. Chest 1991, 99:1027–1029.
9. Abrams GA, Fallon MB: Treatment of hepatopulmonary syndrome with allium sativum (garlic). J Clin Gastroenterol 1998, 27:232–235. This group is conducting animal studies that may provide the first solid foundation for the future investigational treatments that improve hypoxemia due to HPS.
10. Schenk P, Madl C, Rezaie-Majd S, et al.: Methylene blue improves hepatopulmonary syndrome. Ann Int Med 2000, 133:701–706.
11. Poterucha JJ, Krowka MJ, Dickson ER, et al.: Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 1995, 21:96–100. This article demonstrates how embolotherapy dramatically can improve hypoxemia in patients with discrete arteriovenous communications.
12. Riegler JL, Lang KA, Johnson SP, et al.: Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995, 109:978–983.
13. Allgaier HP, Haag K, Ochs A, et al.: Hepatopulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS) [letter]. J Hepatol 1995, 23:102.
14. Selim KM, Akriviadis E, Zuckerman E, et al.: Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998, 93:455–458.
15. Lasch HM, Fried MW, Zacks SL, et al.: Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl 2001, 7:147–149.
16. Corley DA, Scharschmidt B, Bass N, et al.: Lack of efficacy of TIPS for hepatopulmonary syndrome [letter]. Gastroenterology 1997, 113:728–731.
17. De BK, Sen S, Biswas PK, et al.: Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty. Gastroenterology 2000, 118:192–196. A report on special cases of HPS due to portal hypertension associated with inferior vena cava obstruction. Treatment with balloon dilatation cavoplasty obviated liver transplantation.
18. Colobato LA, Spahr L, Martinet JP, et al.: Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut 1999, 39:600–604.
19. Krowka MJ, Porayko MK, Plevak DJ, et al.: Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997, 72:44–53. The largest published series of patients with HPS (n = 81) who underwent liver transplantation.
20. Egawa H, Kasahara M, Inomata Y, et al.: Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications. Transplantation 1999, 67:712–717.
21. Spencer LT, Langham MR, Hoyer MH, et al.: Resolution of hypoxemia in a liver transplant recipient after ligation of a portosystemic shunt. J Pediatr 2000, 137:575–577.
22. Alexander J, Greenough A, Baker A, et al.: Nitric oxide treatment of severe hypoxemia after liver transplantation in hepatopulmonary syndrome. Liver Transpl Surg 1997, 3:54–55.
23. Durand PH, Baujard C, Grosse AL, et al.: Reversal of hypoxemia by inhaled nitric oxide in children with severe hepatopulmonary syndrome, type I, during and after liver transplantation. Transplantation 1998, 65:437–439.
24. Krowka MJ, Frantz RF, McGoon MD, et al.: Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999, 30:641–648. The largest single-institution series, demonstrating acute and long-term improvement in pulmonary hemodynamics with outpatient, continuous 24-hour infusion of epoprostenol in the setting of advance liver disease complicated by pulmonary hypertension.
25. Plotkin JS, Kuo PC, Rubin LJ, et al.: Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998, 65:457–459. The first published case that describes the successful use of epoprostenol to facilitate liver transplantation in the setting of moderate pulmonary hypertension.
26. Kahler CM, Grazidei I, Wiedermann CJ, et al.: Successful use of continuous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 2000, 112:637–640.
27. Findlay JY, Plevak DJ, Krowka MJ, et al.: Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999, 5:362–365.
28. Krowka MJ, Plevak DJ, Findlay JY, et al.: Pulmonary hemodynamics and perioperative cardiopulmonaryrelated mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000, 6:443–450. Specific pulmonary hemodynamic criteria are proposed for patients with PPH considered for OLT.
29. DeWolf AM, Scott VL, Gasior T, et al.: Pulmonary hypertension and liver transplantation [letter]. Anesthesiology 1993, 78:213.
30. Ramsay MAE, Simpson BR, Nguyen AT, et al.: Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997, 3:494–500. Single-institution series describing the spectrum of outcome in PPH when OLT is undertaken.
31. Levy MT, Torzillo P, Bookallil M, et al.: Case report: delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol 1996, 11:734–737.
32. Scott V, DeWolf A, Kang Y, et al.: Reversibility of pulmonary hypertension after liver transplantation: a case report. Transpl Proc 1993, 2:1789–1790.
33. Mandell MS, Duke J: Nitric oxide reduces pulmonary hypertension during hepatic transplantation. Anesthesiology 1994, 81:1538–1542.
34. Krowka MJ: Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin Proc 2000, 75:625–630.
35. Ribas J, Angrill J, Barbera JA, et al.: Isosorbide-5 mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999, 13:210–212.
36. Findlay JY, Harrison BA, Plevak DJ, et al.: Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg 1999, 5:381–388.
37. Ramsay MAE, Spikes C, East CA, et al.: The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 1999, 90:299–301.
38. Tarquino M, Geggel RL, Strauss RS, et al.: Treatment of pulmonary hypertension with inhaled nitric oxide during hepatic transplantation in an adolescent: reversibility of pulmonary hypertension after transplantation. Clin Pediatr 1998, 37:505–510.
39. DeWolf AM, Scott V, Bjerke R, et al.: Hemodynamic effects of inhaled nitric oxide in four patients with severe liver disease and pulmonary hypertension. Liver Transpl Surg 1997, 3:549–597.